Supplementary Figure S5 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study

Key Points

• Average TLS signature expression differs significantly between responders and non-responders to treatment.
• Responders showed TLS expression less than or equal to ypT1N0, while non-responders exhibited ypT2-4aNx or ypTxN1-3.
• Analysis utilized bulk RNA sequencing samples to establish expression profiles for both response groups.
• Findings suggest that the TLS signature may help predict treatment outcomes in urothelial cancer patients.